Article

Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistance

2023-01-09

Abstract excerpt

<title>Abstract</title> <p>Colorectal cancer (CRC) patients with BRAF mutations develop resistance to BRAF inhibitors at very early stage. Understanding the mechanisms involved in resistance to BRAF inhibitors is required to develop novel therapeutic opportunities for this subtype of CRC patients. CRC cells bearing BRAF mutations are mostly sensitive to the abrogation of MKK3, a specific activator of p38MAPKs sig...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b0aaf41c-cb38-5383-b714-1a853b3f342f
DOI: 10.21203/rs.3.rs-2382452/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistanceDOI 10.21203/rs.3.rs-2382452/v1Read

Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistance.Semantic proximity Read

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.Semantic proximity Read

MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancerSemantic proximity Read

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.Semantic proximity Read

AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.Semantic proximity Read

BRAF inhibitors in cancer therapy.Semantic proximity Read

Advances on the BRAF Front in Colorectal Cancer.Semantic proximity Read

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAFi/ErbB1 inhibitorsSemantic proximity Read

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.Semantic proximity Read

Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.Semantic proximity Read

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activationSemantic proximity Read